Release date: 2015-08-21
Gene sequencing Image source: Snowball
Under the new industrial structure, further promotion of the collaboration of the gene sequencing technology industry has become a consensus in the industry. Many experts said that China's gene sequencing industry needs joint efforts in policy, capital, technology and other aspects, strengthen close communication between basic research and development and application areas, and jointly promote the rapid development of the industry.
Recently, in the “Zhongke Zixin BIGIS Second Generation Sequencing System Promotion Conferenceâ€, everyone in the whole place has fixed their eyes on the first BIGene series product with independent intellectual property rights in China. Because of its emergence, it has filled a gap in China's upstream equipment manufacturing in the genetic sequencing industry chain.
Ren Lufeng, chief scientist of Zhongke Zixin, told reporters that BIGIS has made sequencing easier by virtue of its highly integrated modular design and perfect upstream and downstream supporting services. The advent of domestic sequencing instruments not only breaks the situation that genetic sequencing instruments and reagents are heavily dependent on imports, but also reduces the cost of sequencing. It will also drive the development of the entire domestic genetic health industry and ensure the safety of national biological information.
However, compared with the wind and water of the foreign gene sequencing industry, there are still many problems in the domestic progress. Many industry insiders have called for technological innovation to require timely follow-up of industry and capital. The domestic gene sequencing industry needs to combine policies, capital, and technology to promote the sound development of the industry in the form of collaboration in various fields.
Expect to get rid of the import situation
With the rapid iterative updating of sequencing technologies and products, countries have launched precision medicine programs. The advent of the BIGIS second-generation sequencing system has been hailed as “the finishing touch of precision medicine in Chinaâ€.
Before the Zhongke Zixin BIGIS second-generation sequencing system sample display area, the guests showed great interest. According to Ren Lufeng, BIGIS sequencer has three advantages: first, its size is very suitable for small and medium-sized laboratories. Convenient touch screen design does not require users to equip with mouse and keyboard. Secondly, perfect upstream and downstream supporting systems, The “fool-like†operation process makes sequencing easier, even without professional background, it can complete the sequencing operation and solve the customer's worries about the next-generation sequencing analysis. Finally, the localized reagents and chips break the international monopoly and reduce the The cost of sequencing, this is also the biggest highlight of the promotion to attract guests.
Developed by the Institute of Genomics and Semiconductors of the Chinese Academy of Sciences, the BIGIS sequencer is a highly integrated next-generation sequencing platform that integrates a range of electromechanical control, microfluidics, optical and software control systems. After engineering, it has successfully solved a series of key technical problems, completed the whole machine test, and reached and partially surpassed the international mainstream equipment technical indicators. More importantly, its cost is less than 1/3 of imported equipment, and the application cost is lower than 1/5 of imported equipment, which will completely change the situation that China's genetic sequencer is completely dependent on imports.
Ren Lufeng said that BIGIS sequencing system can provide a complete set of sequencing solutions including whole genome sequencing, targeted region resequencing, digital expression profiling, etc., widely used in the etiology identification and genetic diagnosis of infectious diseases, genetic diseases genes. Diagnosis and screening, tumor and blood disease genetic testing and individualized diagnosis and treatment, inspection and quarantine, and pharmacogenomics and other health and disease-related fields.
At present, Zhongke Zixin is preparing for the preparatory work before the large-scale production of the BIGIS second-generation sequencer. It is expected to be officially put into mass production at the end of this year or early next year.
"In the future, we will establish a research institute in the United States, cooperate with internationally renowned data companies, and establish the Zhongke Zixin Industrial Park to realize the integration of the upstream and downstream industries of the entire gene sequencing system. The total annual output will reach 10,000 units. By then, Whether it is a newborn baby or an old man, the old ones will use their own sequencer for gene sequencing, and the per capita cost will be reduced to 1,000 yuan, ending the phenomenon of antibiotics and drug abuse." Yin Jinlong, chairman of Zhongke Zixin, promised.
Industrial development "blocking the road"
In Ren Lufeng's view, as China's first independent intellectual property rights sequencer, BIGIS products will be more "earth" and more in line with national bio-information security requirements. It is expected to gain market recognition with competitive technology and price advantage. .
According to a study by Markets & Markets, the global market for second-generation gene sequencing in 2014 was $2.5 billion, and is expected to reach $8.7 billion in 2020, a compound annual growth rate of 23%. Among them, the second generation gene sequencing is the fastest growing sub-sector in the field of genetics, surpassing gene chip and PCR technology.
Faced with the potential market prospects of gene sequencing, Wang Deping, director of the Biotechnology Development Center of the Ministry of Science and Technology, said that gene sequencing technology and product development will also be listed as an important part of China's 13th Five-Year Plan.
"Gene sequencing technology is the basic technology in the fields of life sciences, disease treatment, etc. Through in-depth information mining, many industries can be derived. Precision medicine and mobile medicine are based on sequencing technology, and biological related strategies such as brain science and development are also It is inseparable from sequencing technology." Wang Deping revealed that the country may publish guidelines on precision medicine, brain science and development at the end of this year as a strategic task for the 13th Five-Year National Science and Technology Development.
It is worth noting that although China has achieved certain results in the development of gene sequencing technology and its status in the international arena, the industry as a whole still has many problems.
Ding Guohui, a researcher at the Shanghai Bioinformatics Research Center, said that at present, there is a lack of industry standards in the market competition for the sequencing industry. For example, data quality control standards, instrument certification system standards, etc., especially for clinical, more stringent accusation standards system. Wu Dongping, a professor at the School of Information Science and Engineering at Fudan University, also held a similar view: "There are a lot of current sequencing service companies, but due to the lack of uniform industry standards, the interests are forced, and there is a tendency to fall into price wars."
In addition, Lu Zuhong, a professor at the School of Engineering of Peking University, also pointed out that the foreign gene sequencing technology industry is booming, and it pays great attention to the follow-up of policies and capital. The domestic genetic sequencing industry is not easy to develop. It is more difficult to do domestic serializers. The lack of communication and collaboration, the lack of institutional innovation, affects the innovation and development of the domestic gene sequencing technology industry.
Yu Yude, a researcher at the Institute of Semiconductors of the Chinese Academy of Sciences, also said that at present, domestic investment in the genetic sequencing industry is still insufficient. After technological innovation, capital cannot be quickly followed up. New technologies are not focused enough, and technology requires industry and capital support.
"At present, there is not enough investment in this field, lack of professional talents, few leading talents, less innovation ability and technical products. It is necessary to take a new level in the research and development of new technologies and new products, to achieve the needs of various industries, and to Bigger and stronger.†Wang Deping added.
Looking forward to achieving win-win cooperation
Under the new industrial structure, further promotion of the collaboration of the gene sequencing technology industry has become a consensus in the industry. Many experts said that China's gene sequencing industry needs joint efforts in policy, capital, technology and other aspects, strengthen close communication between basic research and development and application areas, and jointly promote the rapid development of the industry.
Sheng Sizhen, founder of Shenzhen Huayinkang Gene Technology Co., Ltd. believes that the healthy and healthy development of any industry needs multi-party cooperation. With the rapid development of the sequencing industry, various applications are continuously developed and the industrial chain is taking shape. On the one hand, with the gradual maturity of sequencing technology, application development is only a natural process; on the other hand, the opportunity of the gene sequencing industry has come, and any industry development here, joint promotion can promote the rapid development of the industry.
Under the joint appeal of the industry, the China Gene Sequencing Technology and Industry Promotion Alliance was also established in the afternoon of the system promotion meeting. Sheng Sizhen said that the instrument is focused on technology research and development. At present, most of the core technologies of the sequencer originate from abroad. After the establishment of the alliance, each of them can take the initiative and make progress together, occupying a place in technology research and development, and curbing the unreasonable price increase of some foreign companies.
"The future development requires multi-party cooperation and cooperation, support at the capital level. Simply relying on the state is not a long-term survival. It must have sufficient self-hematopoietic capacity and use capital to promote technological development. This is also one of the functions of the alliance." Ren Lufeng Added.
Through in-depth discussion and analysis, the participating experts agreed that the alliance should play six main functions: to keep the members of the alliance in sync with the frontiers of science and technology and technology; to synchronize technology development and innovation with national needs; to promote industry collaboration and exchange; to promote the integration of research and capital Develop industry standards; promote industry development.
With the continuous innovation of domestic technology and capital follow-up, Lu Zuhong is full of confidence in the future development of China's genetic sequencer: "The ideal sequencer should be more convenient, complicated, reagent-free, no need for library amplification, and long read length. Long, high throughput, high precision, low cost, and faster, perhaps the third, fourth, and fifth generation sequencing technologies can be realized soon."
Source: Chinese Journal of Science
Sunflower Seeds,Sunflower Kernels,Bulk Sunflower Seeds,Shelled Sunflower Seeds
Wuyuan county dafeng oil food co.,ltd , https://www.dafengfood.com.cn